Venaxis: Transforming Appendicitis Diagnosis with Rapid Blood Testing
About Us
Venaxis is a Colorado-based in vitro diagnostic company focused on developing and commercializing its unique multi-biomarker diagnostic test, the APPY1 Test. Designed to aid in the identification of patients at low risk for acute appendicitis, the APPY1 Test is a simple, rapid blood test that may help physicians manage the large number of children and adolescents who enter hospital emergency departments with abdominal pain, suspected of acute appendicitis. Determining whether a patient requires emergency surgery for appendicitis is critical and current practices have important limitations.
careers
At Venaxis, we know our vision of becoming a leader in innovative tests for appendicitis is only possible due to the talent, experience and commitment of our employees.
We believe in fostering a collaborative and goal oriented working environment that aligns the organization and our successes. Join Venaxis and be a part of our innovative and creative team as we make a difference in the lives of millions of patients around the world.
APPY1 Test as a Rapid, Radiation-Free Alternative
Diagnostic CT imaging is widely recognized for its high accuracy in detecting acute appendicitis, yet its use is constrained by substantial cost and notable long-term health risks. Exposure to ionizing radiation is particularly concerning in pediatric and adolescent populations, who not only have heightened sensitivity to radiation but also represent the group at highest risk for appendicitis. In clinical practice, the limitations of imaging often lead to precautionary hospital admissions to prevent the potentially serious consequences of appendiceal rupture at home. These admissions contribute to increased healthcare expenditures and patient burden. The introduction of a simple, rapid blood test, such as the APPY1 Test, provides clinicians with a valuable adjunct diagnostic tool. By identifying patients at low risk for acute appendicitis, this test may support more conservative patient management strategies. Potential benefits include reducing reliance on CT imaging, minimizing radiation exposure, shortening hospital stays, and lowering both direct and indirect healthcare costs all while maintaining patient safety and clinical efficacy.
APPY1 Test: A Smarter Solution for Appendicitis Diagnosis
The APPY1 Test represents a significant advancement in the diagnostic management of suspected acute appendicitis, addressing one of the most common and challenging presentations in emergency medicine. As a simple and rapid blood-based assay, APPY1 integrates seamlessly into existing diagnostic workflows, offering clinicians an objective biochemical tool to support early decision-making. The test is specifically designed to help identify patients at low risk for acute appendicitis, thereby reducing diagnostic uncertainty and optimizing the use of imaging resources such as CT scans and ultrasounds.
By combining the analysis of specific biomarkers associated with inflammatory and immune responses, the APPY1 Test provides physicians with reliable information that complements clinical evaluation, laboratory results, and radiologic findings. This multi-faceted approach enhances the accuracy and efficiency of patient triage, supporting evidence-based strategies that minimize the likelihood of both missed diagnoses and unnecessary interventions. In emergency and acute care settings where rapid and accurate differentiation between appendicitis and other causes of abdominal pain is crucial the APPY1 Test empowers clinicians to make timely, confident, and patient-centered decisions, improving outcomes while optimizing healthcare resources.
Reducing Dependence on Diagnostic Imaging
Conventional diagnostic strategies for acute appendicitis frequently depend on computed tomography (CT) imaging, which remains the gold standard for confirming diagnosis due to its high sensitivity and specificity. However, despite its diagnostic utility, CT imaging poses several clinical, economic, and safety-related challenges. The procedure is expensive and resource-intensive, often leading to delays in diagnosis and treatment, especially in emergency departments with high patient volumes or limited imaging capacity. Moreover, exposure to ionizing radiation presents a considerable long-term health risk, particularly for pediatric and adolescent populations, who not only have a higher lifetime susceptibility to radiation-induced malignancies but also represent the demographic with the highest incidence of appendicitis.
The APPY1 Test offers a non-invasive, radiation-free alternative that can significantly decrease reliance on diagnostic imaging without compromising clinical accuracy. By integrating this rapid biochemical assay early in the diagnostic pathway, clinicians can more confidently identify patients at low risk of appendicitis, thus reserving CT scans for cases where imaging is truly necessary. This approach not only helps minimize unnecessary radiation exposure but also reduces healthcare costs, shortens emergency department waiting times, and enhances overall patient safety. In doing so, APPY1 supports a more sustainable, patient-centered model of care, where advanced diagnostics work in harmony with clinical judgment to optimize outcomes and resource utilization.
Enhancing Patient Management and Outcomes
In many healthcare settings, patients presenting with nonspecific or inconclusive abdominal symptoms are frequently admitted for observation to prevent the risk of appendiceal rupture, a potentially life-threatening complication. While this cautious approach prioritizes patient safety, it also leads to prolonged hospital stays, increased healthcare expenditures, and overutilization of limited hospital resources. Such admissions often include patients who ultimately do not have appendicitis, highlighting the urgent need for more accurate, rapid, and cost-effective triage tools.
The APPY1 Test provides clinicians with objective biochemical data that enhances clinical assessment by helping to differentiate low-risk patients from those requiring further investigation or surgical consultation. By incorporating APPY1 results into the diagnostic pathway, healthcare teams can confidently adopt more conservative management strategies, facilitating earlier patient discharge and reducing unnecessary admissions. This not only alleviates hospital congestion but also decreases the emotional and financial burden on patients and their families.
Ultimately, the implementation of the APPY1 Test contributes to better resource allocation, faster diagnostic workflows, and improved patient comfort and satisfaction. By supporting evidence-based decision-making and minimizing invasive procedures, APPY1 exemplifies the shift toward precision-driven, patient-centered emergency care, where clinical efficiency aligns with safety and quality outcomes.
Innovation That Delivers Performance
At the intersection of innovation and clinical excellence, the APPY1 Test establishes a new benchmark for diagnostic efficiency in suspected appendicitis. Designed with both clinicians and patients in mind, the test combines simplicity, speed, and reliability, providing actionable results within a short timeframe that seamlessly fit into emergency department and clinical workflows. Its intuitive design ensures minimal operational complexity, allowing healthcare teams to integrate the test without disrupting existing protocols or overburdening staff.
Beyond its practical advantages, APPY1 embodies a transformative approach to patient care. By reducing dependence on costly imaging and minimizing unnecessary hospital admissions, the test supports a safer, faster, and more cost-effective diagnostic pathway. This innovation not only enhances patient safety and comfort by lowering exposure to ionizing radiation but also improves resource allocation and operational efficiency for healthcare providers.
In essence, APPY1 demonstrates how cutting-edge diagnostic innovation can be harmonized with real-world clinical practicality, delivering tangible benefits across the healthcare continuum. From accelerating early detection to optimizing hospital workflow, APPY1 represents a forward-thinking solution that empowers providers, improves outcomes, and reinforces the value of precision-driven, patient-centered care.
A New Benchmark in Appendicitis Diagnosis
At the intersection of innovation and clinical excellence, the APPY1 Test establishes a new standard for the rapid and accurate diagnosis of suspected appendicitis. Traditional methods, such as physical examination, laboratory tests, and imaging, often present limitations in speed, precision, and safety, particularly for pediatric and adolescent patients. APPY1 addresses these challenges by delivering reliable results within a short timeframe, enabling clinicians to make timely, informed decisions. Its user-friendly design integrates seamlessly into emergency department workflows, requiring minimal training and operational adjustments. This simplicity ensures that healthcare teams can deploy the test without disrupting existing protocols, reducing workflow bottlenecks and supporting efficient patient triage.
Transforming Patient Care
Beyond operational efficiency, APPY1 represents a paradigm shift in patient-centered care. By identifying individuals at low risk for acute appendicitis, the test helps clinicians avoid unnecessary imaging procedures and hospital admissions. This not only reduces healthcare costs but also protects patients from potential harm, such as exposure to ionizing radiation from CT scans, which carries long-term health risks, especially for younger populations. Furthermore, minimizing unnecessary hospital stays improves patient comfort and satisfaction, alleviating the stress and anxiety often associated with emergency care. Through this approach, APPY1 enhances safety, efficiency, and quality of care across the patient journey.
Evidence-Based Decision Making
The APPY1 Test represents a paradigm shift in the field of acute appendicitis diagnostics by harnessing the power of biomarker-driven decision-making. Traditional diagnostic pathways often rely on subjective symptom assessment, physical examination, and imaging modalities such as CT scans or ultrasounds, which can be time-consuming, costly, and occasionally inconclusive. In contrast, APPY1 delivers objective, evidence-based insights that allow clinicians to accurately stratify patients according to their individualized risk of appendicitis. Low-risk patients can be safely managed conservatively, minimizing exposure to unnecessary surgical procedures, anesthesia, and hospitalization, while high-risk patients receive prompt, targeted interventions that reduce the likelihood of complications. By enabling precise, data-guided clinical decisions, APPY1 not only decreases diagnostic uncertainty but also improves patient outcomes, enhances operational efficiency, and optimizes the allocation of healthcare resources. This approach exemplifies the broader potential of biomarker-informed diagnostics to transform patient care, moving clinical practice toward a model that is both safer and more cost-effective.
Laboratorians
The laboratory plays a significant role in providing timely and objective clinical information. This information is critically important particularly for suspected acute appendicitis (AA) patients.
White blood cell count (WBC) may be routinely ordered by the physician, but the test has demonstrated limited utility as a single marker, even when it is combined with signs and symptoms suggestive of AA.1 C-reactive protein (CRP) or other inflammatory markers may also be ordered, however, individually these may also provide confounding information, as the source of the inflammation may not be specific to appendicitis.
Ultrasound (US) is usually effective when the appendix can be clearly visualized. Computed tomography (CT) scan is accurate in the diagnosis of AA, again when the appendix can be clearly visualized, but the use of CT carries significant risk as a result of increased exposure to ionizing radiation.2-5 In an effort to minimize the reliance on abdominal US or CT, the APPY System provides the laboratory a means to provide additional clinical information to the ED.
The APPY System is comprised of an APPY Reader, a fluorescence detection instrument, the APPY1 Test, and three (3) means for quality control for assessing the performance of the system. The APPY System is designed for use in a hospital laboratory.
The APPY1 Test is a qualitative In Vitro Diagnostic Multivariate Index Assay (IVDMIA) used to aid in the identification of patients at low risk for acute appendicitis. The APPY1 Test measures myeloid-related protein heterocomplex MRP 8/14 (calprotectin) and C-reactive protein (CRP) in EDTA-plasma by lateral flow immunoassay.
The quantitative MRP 8/14 and CRP results, in addition to the laboratory generated WBC count, are then computed by a preprogrammed proprietary algorithm to give an APPY1 Test score and a qualitative interpretation.
